The induction of insulin antibodies and the development of an insulin allergy were observed in a male diabetic patient treated with insulin during α-IFN therapy of renal cell carcinoma. Diabetes and renal cell carcinoma were diagnosed at the same time. The patient was treated with biosynthetic human insulin and nephrectomy was performed. Four months later, antineoplastic chemotherapy was started (α-IFN, vinblastin). Six weeks after initiation of α-IFN injections, the patient reported signs of insulin allergy. Significant titers of insulin antibodies of both the IgG and IgE subclasses were found in the serum at that time and during follow-up, but not before the treatment with α-IFN. None of the other autoantibodies investigated were positive.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.